BMND15
MCID: BNM029
MIFTS: 48

Bone Mineral Density Quantitative Trait Locus 15 (BMND15)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 15

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 15:

Name: Bone Mineral Density Quantitative Trait Locus 15 57 6 39
Osteoporosis 57 70
Metaphyseal Fracture, Susceptibility to 57
Compression Fracture, Susceptibility to 57
Osteoporosis, Susceptibility to 57
Fractures, Compression 70
Metaphyseal Fractures 6
Metaphyseal Fracture 57
Compression Fracture 57
Bmnd15 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal recessive
autosomal dominant


HPO:

31
bone mineral density quantitative trait locus 15:
Inheritance autosomal dominant inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM® 57 613418
MedGen 41 C3150680
SNOMED-CT via HPO 68 258211005 263681008 64859006
UMLS 70 C0029456 C0521169

Summaries for Bone Mineral Density Quantitative Trait Locus 15

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 15, also known as osteoporosis, is related to bone mineral density quantitative trait locus 8 and osteoporosis, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Bone Mineral Density Quantitative Trait Locus 15 is MIR2861 (MicroRNA 2861). The drugs Clobetasol and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and bone marrow, and related phenotype is osteoporosis.

More information from OMIM: 613418

Related Diseases for Bone Mineral Density Quantitative Trait Locus 15

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 15 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1118)
# Related Disease Score Top Affiliating Genes
1 bone mineral density quantitative trait locus 8 32.2 PDLIM4 CALCR
2 osteoporosis 32.0 PDLIM4 MIR2861 CALCR
3 osteoporosis, juvenile 11.8
4 osteoporosis-pseudoglioma syndrome 11.7
5 hajdu-cheney syndrome 11.5
6 glucocorticoid-induced osteoporosis 11.5
7 nephrolithiasis/osteoporosis, hypophosphatemic, 1 11.5
8 nephrolithiasis/osteoporosis, hypophosphatemic, 2 11.5
9 juvenile primary osteoporosis 11.5
10 osteoporosis and oculocutaneous hypopigmentation syndrome 11.3
11 hypophosphatemic nephrolithiasis/osteoporosis 11.3
12 bone mineral density quantitative trait locus 16 11.3
13 bone mineral density quantitative trait locus 18 11.2
14 bone disease 11.2
15 bone resorption disease 11.2
16 rickets 11.1
17 premature menopause 11.1
18 werner syndrome 11.1
19 syndromic x-linked intellectual disability snyder type 11.1
20 multicentric osteolysis, nodulosis, and arthropathy 11.1
21 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 11.1
22 hyperparathyroidism 11.1
23 aromatase deficiency 11.1
24 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 11.0
25 winchester syndrome 11.0
26 bone mineral density quantitative trait locus 12 11.0
27 lysinuric protein intolerance 11.0
28 geroderma osteodysplasticum 11.0
29 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 11.0
30 mucolipidosis iii alpha/beta 11.0
31 nestor-guillermo progeria syndrome 11.0
32 ehlers-danlos syndrome, classic-like, 2 11.0
33 hypogonadotropic hypogonadism 11.0
34 hyperthyroidism 11.0
35 anorexia nervosa 10.9
36 cerebrotendinous xanthomatosis 10.9
37 cholangitis, primary sclerosing 10.9
38 bone mineral density quantitative trait locus 3 10.9
39 celiac disease 1 10.9
40 mental retardation, x-linked, syndromic, snyder-robinson type 10.9
41 spondyloocular syndrome 10.9
42 cleidocranial dysplasia 10.9
43 acth-secreting pituitary adenoma 10.9
44 cutis laxa osteoporosis 10.9
45 systemic mastocytosis 10.9
46 hyperparathyroidism 1 10.9
47 dyskeratosis congenita, autosomal recessive 1 10.9
48 hyaline fibromatosis syndrome 10.9
49 mucolipidosis iii gamma 10.9
50 prader-willi habitus, osteopenia, and camptodactyly 10.9

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 15:



Diseases related to Bone Mineral Density Quantitative Trait Locus 15

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 15

Human phenotypes related to Bone Mineral Density Quantitative Trait Locus 15:

31
# Description HPO Frequency HPO Source Accession
1 osteoporosis 31 HP:0000939

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Skeletal:
osteoporosis
compression fractures (in homozygotes)
metaphyseal fractures (in homozygotes)

Clinical features from OMIM®:

613418 (Updated 05-Apr-2021)

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 15:


tremor; back pain; angina pectoris; sciatica; equilibration disorder; muscle cramp; pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 15

Drugs for Bone Mineral Density Quantitative Trait Locus 15 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 396)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Linagliptin Approved Phase 4 668270-12-0 10096344
4
Atorvastatin Approved Phase 4 134523-00-5 60823
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
7 Strontium ranelate Approved, Withdrawn Phase 4 135459-87-9
8
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
11
Racepinephrine Approved Phase 4 329-65-7 838
12
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
13
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
14
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
15
Ribavirin Approved Phase 4 36791-04-5 37542
16
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
17
Gliclazide Approved Phase 4 21187-98-4 3475
18
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
19
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
20
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
21
Demeclocycline Approved Phase 4 127-33-3 5311063
22
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
23
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
24
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
25
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
26
Lactitol Approved, Investigational Phase 4 585-86-4 157355
27
Tibolone Approved, Investigational Phase 4 5630-53-5
28
Liraglutide Approved Phase 4 204656-20-2 44147092
29
Morphine Approved, Investigational Phase 4 57-27-2 5288826
30
tannic acid Approved Phase 4 1401-55-4
31
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
32
Exemestane Approved, Investigational Phase 4 107868-30-4 60198
33
Abaloparatide Approved, Investigational Phase 4 247062-33-5
34
Cinacalcet Approved Phase 4 226256-56-0 156419
35
Acetaminophen Approved Phase 4 103-90-2 1983
36
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
37
Ibuprofen Approved Phase 4 15687-27-1 3672
38
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
39
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
40
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
41
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
42
Pravastatin Approved Phase 4 81093-37-0 54687
43
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
45
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
47
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4 53-43-0 5881
48
Menatetrenone Investigational Phase 4 863-61-6, 56973-41-2 5282367
49
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
50 Progestins Phase 4

Interventional clinical trials:

(show top 50) (show all 1391)
# Name Status NCT ID Phase Drugs
1 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
2 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Unknown status NCT03926377 Phase 4
3 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
4 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
5 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
6 The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury Unknown status NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
7 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
8 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
9 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
10 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
11 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
12 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
13 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
14 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
15 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
16 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
17 Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures Completed NCT01383616 Phase 4
18 Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study Completed NCT00371956 Phase 4 raloxifene;placebo
19 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
20 Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study Completed NCT02808988 Phase 4
21 The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women Completed NCT00460057 Phase 4 Alendronate
22 The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients - A Prospective, Randomised, Controlled Clinical Trial Completed NCT00114556 Phase 4 zoledronic acid
23 The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass Completed NCT02499237 Phase 4 Denosumab;Zoledronic acid
24 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
25 High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
26 A Multi Centre, Randomised, Open Label, Cross-over Study to Evaluate the Percentage of False Negative Osteoporosis Diagnosis's Using the Standard Case-finding Procedure as Described by the Dutch Institute for Healthcare (CBO) and to Determine the Preference of Adult Osteoporosis Patients Between Once Monthly Dosing of Ibandronate (150 mg) and Once Weekly Dosing of Alendronate (70 mg) Completed NCT00327990 Phase 4 Ibandronate;Alendronate
27 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
28 OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study Completed NCT00592917 Phase 4
29 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
30 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
31 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
32 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
33 Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy Completed NCT00927186 Phase 4 Teriparatide;Zoledronic Acid
34 Antiepileptic Drugs and Osteoporotic Prevention Trial Completed NCT00869622 Phase 4 Risedronate;Placebo + Calcium and Vitamin D
35 Fracture (FX) Improvement With Teriparatide: FiX-IT Study Completed NCT01705587 Phase 4 teriparatide
36 Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR Completed NCT01679899 Phase 4 Vildagliptin;Gliclazide MR
37 Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty Completed NCT00810043 Phase 4
38 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
39 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily Completed NCT00453492 Phase 4 risedronate sodium
40 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
41 Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Postmenopausal Osteoporosis Without Vertebral Fractures Completed NCT00271713 Phase 4 ibandronate, calcium and vitamin D;placebo,calcium and vitamin D
42 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
43 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
44 A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women Completed NCT00402441 Phase 4 Risedronate (HMR4003)
45 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
46 Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549 Completed NCT00081653 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
47 Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00035256 Phase 4 teriparatide;raloxifene HCl;placebo
48 Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study. Completed NCT00377234 Phase 4 Risedronate;ibandronate [Bonviva/Boniva]
49 Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis Completed NCT00191425 Phase 4 Teriparatide;Raloxifene
50 Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide Completed NCT00130403 Phase 4 risedronate sodium

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 15

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
SODIUM FLUORIDE PWDR

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 15

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 15

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 15:

40
Bone, Prostate, Bone Marrow, Breast, Spinal Cord, Kidney, Thyroid

Publications for Bone Mineral Density Quantitative Trait Locus 15

Articles related to Bone Mineral Density Quantitative Trait Locus 15:

(show top 50) (show all 30004)
# Title Authors PMID Year
1
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. 57 6 61
19920351 2009
2
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 6
12908099 2003
3
Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. 6
9817931 1998
4
Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. 6
9571205 1998
5
Allelic variants of human calcitonin receptor in the Japanese population. 6
9003491 1997
6
Trelagliptin stimulates osteoblastic differentiation by increasing runt-related transcription factor 2 (RUNX2): a therapeutic implication in osteoporosis. 61
33734011 2021
7
Ficus deltoidea promotes bone formation in streptozotocin-induced diabetic rats. 61
33399485 2021
8
Lithium chloride promotes osteogenesis and suppresses apoptosis during orthodontic tooth movement in osteoporotic model via regulating autophagy. 61
33778189 2021
9
Severe injury-induced osteoporosis and skeletal muscle mineralization: Are these related complications? 61
33490313 2021
10
Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis. 61
33665236 2021
11
Effect of ErhBMP-2-loaded β-tricalcium phosphate on ulna defects in the osteoporosis rabbit model. 61
33364265 2021
12
Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab. 61
33506078 2021
13
3D‑printed Ti6Al4V scaffolds combined with pulse electromagnetic fields enhance osseointegration in osteoporosis. 61
33786622 2021
14
Longitudinal effects of low-intensity pulsed ultrasound on osteoporosis and osteoporotic bone defect in ovariectomized rats. 61
33561635 2021
15
High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: A prospective cohort study. 61
33610904 2021
16
Therapeutic potential of iron chelators on osteoporosis and their cellular mechanisms. 61
33601146 2021
17
Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid. 61
33135182 2021
18
Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis. 61
32558699 2021
19
Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis. 61
32862655 2021
20
Osteoporosis and fractures in rheumatoid arthritis. 61
33651725 2021
21
Bone material properties and response to teriparatide in osteoporosis due to WNT1 and PLS3 mutations. 61
33618074 2021
22
Osteoporosis and osteoblasts cocultured with adipocytes inhibit osteoblast differentiation by downregulating histone acetylation. 61
33124698 2021
23
Total glycosides and polysaccharides of Cistanche deserticola prevent osteoporosis by activating Wnt/β-catenin signaling pathway in SAMP6 mice. 61
33549763 2021
24
Quercetin and vitamin E alleviate ovariectomy-induced osteoporosis by modulating autophagy and apoptosis in rat bone cells. 61
33030247 2021
25
Syndecan-3 enhances anabolic bone formation through WNT signaling. 61
33769615 2021
26
Osteogenic effects of the peptide fraction derived from pepsin-hydrolyzed bovine lactoferrin. 61
33551166 2021
27
Circ-ITCH sponges miR-214 to promote the osteogenic differentiation in osteoporosis via upregulating YAP1. 61
33795657 2021
28
Oxidative stress induces downregulation of TP53INP2 and suppresses osteogenic differentiation of BMSCs during osteoporosis through the autophagy degradation pathway. 61
33636337 2021
29
[Osteoporosis-Update 2021]. 61
33780987 2021
30
Long-term evaluation of anabolic and anti-resorptive agents in adults with familial osteoporosis due to pro205ala variant of the col1a1 gene. 61
33796912 2021
31
Anti-perimenopausal osteoporosis effects of Erzhi formula via regulation of bone resorption through osteoclast differentiation: A network pharmacology-integrated experimental study. 61
33444724 2021
32
Green tea extract synergistically enhances the effectiveness of an antiresorptive drug on management of osteoporosis induced by ovariectomy in a rat model. 61
33732301 2021
33
Biomechanical Evaluation of Oblique Lumbar Interbody Fusion with Various Fixation Options: A Finite Element Analysis. 61
33619850 2021
34
Bone Mineral Density: Clinical Relevance and Quantitative Assessment. 61
33310738 2021
35
Oxidative Stress-Induced Hypermethylation of KLF5 Promoter Mediated by DNMT3B Impairs Osteogenesis by Diminishing the Interaction with β-Catenin. 61
33588625 2021
36
Approaches to Fracture Risk Assessment and Prevention. 61
33523422 2021
37
Agastache rugosa ethanol extract suppresses bone loss via induction of osteoblast differentiation with alteration of gut microbiota. 61
33626428 2021
38
Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. 61
33382995 2021
39
Hydrophilic titanium surface modulates early stages of osseointegration in osteoporosis. 61
33368275 2021
40
Osteoporosis prevention in an extraordinary hibernating bear. 61
33450432 2021
41
Effect of Education on Preventive Behaviors of Osteoporosis in Adolescents: A Systematic Review and Meta-Analysis. 61
32586215 2021
42
The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis. 61
32914348 2021
43
Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose? 61
33635520 2021
44
Bone densitometry categories as a salient distracting feature in the modern clinical pathways of osteoporosis care: A retrospective 20-year cohort study. 61
33484888 2021
45
Clinical guidelines for the application of panoramic radiographs in screening for osteoporosis. 61
33620644 2021
46
Stroke and osteoporosis: a Taiwan cohort study. 61
32165547 2021
47
By inhibiting ADCY5, miR-18a-3p promotes osteoporosis and possibly contributes to spinal fracture. 61
33684620 2021
48
In Silico Network Analysis of Ingredients of Cornus officinalis in Osteoporosis. 61
33795629 2021
49
Opportunistic osteoporosis screening in multi-detector CT images using deep convolutional neural networks. 61
33001308 2021
50
Interplay between mineral crystallinity and mineral accumulation in health and postmenopausal osteoporosis. 61
33582361 2021

Variations for Bone Mineral Density Quantitative Trait Locus 15

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 15:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LOC113839511 , MIR2861 NR_036055.1(MIR2861):n.33C>G SNV association 106 rs794728003 GRCh37: 9:130548229-130548229
GRCh38: 9:127785950-127785950
2 PDLIM4 RIL, -3333T-C SNV risk factor 6348 GRCh37:
GRCh38:
3 CALCR NM_001742.4(CALCR):c.1340T>C (p.Leu447Pro) SNV risk factor 17636 rs1801197 GRCh37: 7:93055753-93055753
GRCh38: 7:93426441-93426441
4 TRPV6 NM_018646.6(TRPV6):c.1978G>C (p.Gly660Arg) SNV Likely pathogenic 818220 rs780306040 GRCh37: 7:142570162-142570162
GRCh38: 7:142872409-142872409

Expression for Bone Mineral Density Quantitative Trait Locus 15

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 15.

Pathways for Bone Mineral Density Quantitative Trait Locus 15

GO Terms for Bone Mineral Density Quantitative Trait Locus 15

Sources for Bone Mineral Density Quantitative Trait Locus 15

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....